Success in Phase III trial of NovoTTF-100A for Brain Cancer - Novocure

Novocure has announced that the NovoTTF-100A System (tumor treating fields therapy) in combination with standard-of-care temozolomide chemotherapy extended both progression-free survival (PFS) and overall survival (OS) compared to temozolomide alone in patients with newly diagnosed Glioblastoma (GBM). Patients treated with TTFields together with temozolomide demonstrated a significant increase in PFS compared to temozolomide alone (median PFS of 7.1 months compared to 4.0 months, respectively). Patients treated with TTFields together with temozolomide demonstrated a significant increase in OS compared to temozolomide alone (median OS of 19.6 months compared to 16.6 months, respectively).

Finally, the percentage of patients alive at 2 years in the TTFields together with temozolomide arm was 43% compared to 29% in the temozolomide alone arm. Based on the interim analysis results, the Independent Monitoring Committee for the EF-14 trial recommended that the trial be stopped early and that Novocure provide access to TTFields for patients on the temozolomide alone arm. The EF-14 Phase III trial data were presented at the Society for Neuro-Oncology 2014 Annual Meeting.